G Ackermann

1.4k total citations
39 papers, 1.1k citations indexed

About

G Ackermann is a scholar working on Infectious Diseases, Epidemiology and Molecular Medicine. According to data from OpenAlex, G Ackermann has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 12 papers in Epidemiology and 8 papers in Molecular Medicine. Recurrent topics in G Ackermann's work include Clostridium difficile and Clostridium perfringens research (17 papers), Antimicrobial Resistance in Staphylococcus (10 papers) and Viral gastroenteritis research and epidemiology (8 papers). G Ackermann is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (17 papers), Antimicrobial Resistance in Staphylococcus (10 papers) and Viral gastroenteritis research and epidemiology (8 papers). G Ackermann collaborates with scholars based in Germany, United States and Netherlands. G Ackermann's co-authors include Arne C. Rodloff, B. Löffler, Reiner Schaumann, Michael J. Gerber, Marina C. Claros, Ellie J. C. Goldstein, Stuart H. Cohen, Joseph Silva, Yajarayma J. Tang and Jeffrey P. Henderson and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

G Ackermann

38 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G Ackermann Germany 21 744 477 174 160 131 39 1.1k
Mercedes Marı́n Spain 22 683 0.9× 495 1.0× 214 1.2× 179 1.1× 218 1.7× 47 1.0k
Jin‐Yong Jeong South Korea 24 447 0.6× 529 1.1× 286 1.6× 218 1.4× 222 1.7× 47 1.4k
Steven P Gelone United States 17 761 1.0× 663 1.4× 87 0.5× 172 1.1× 43 0.3× 52 1.2k
Jennifer S. McDanel United States 13 667 0.9× 357 0.7× 157 0.9× 178 1.1× 337 2.6× 25 1.1k
M. Marín Spain 18 698 0.9× 604 1.3× 132 0.8× 238 1.5× 89 0.7× 28 1.1k
Jin-Won Chung South Korea 18 526 0.7× 446 0.9× 109 0.6× 116 0.7× 114 0.9× 70 1.2k
Orna Nitzan Israel 17 316 0.4× 536 1.1× 234 1.3× 147 0.9× 127 1.0× 46 1.1k
Hiroshige Mikamo Japan 20 391 0.5× 585 1.2× 167 1.0× 157 1.0× 152 1.2× 170 1.3k
Nicole J. Pultz United States 20 753 1.0× 193 0.4× 432 2.5× 79 0.5× 146 1.1× 24 1.3k
Ali Hassoun United States 10 449 0.6× 208 0.4× 214 1.2× 81 0.5× 154 1.2× 42 784

Countries citing papers authored by G Ackermann

Since Specialization
Citations

This map shows the geographic impact of G Ackermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Ackermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Ackermann more than expected).

Fields of papers citing papers by G Ackermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Ackermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Ackermann. The network helps show where G Ackermann may publish in the future.

Co-authorship network of co-authors of G Ackermann

This figure shows the co-authorship network connecting the top 25 collaborators of G Ackermann. A scholar is included among the top collaborators of G Ackermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Ackermann. G Ackermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ackermann, G, et al.. (2023). Dose-response studies on the genotoxic potential of estragole and its metabolite 1‘-hydroxyestragole in human liver cells. Zeitschrift für Phytotherapie. 44(S 01). S18–S18.
2.
Henschler, Reinhard, Raymund Buhmann, Thorsten Kaiser, et al.. (2021). Sensitivity of SARS-CoV-2 antibody tests with late convalescent sera. SHILAP Revista de lepidopterología. 1(3). 100038–100038. 5 indexed citations
3.
Schäpe, Stephanie Serena, Florian Schattenberg, Susann Müller, et al.. (2020). The Activation of Mucosal-Associated Invariant T (MAIT) Cells Is Affected by Microbial Diversity and Riboflavin Utilization in vitro. Frontiers in Microbiology. 11. 755–755. 20 indexed citations
4.
5.
Löffler, B., et al.. (2007). Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile. Diagnostic Microbiology and Infectious Disease. 59(1). 1–5. 47 indexed citations
6.
Tang-Feldman, Yajarayma, Jeffrey P. Henderson, G Ackermann, et al.. (2005). Prevalence of the ermB Gene in Clostridium difficile Strains Isolated at a University Teaching Hospital from 1987 through 1998. Clinical Infectious Diseases. 40(10). 1537–1540. 10 indexed citations
7.
Ackermann, G. (2003). Prevalence and association of macrolide-lincosamide- streptogramin B (MLSB) resistance with resistance to moxifloxacin in Clostridium difficile. Journal of Antimicrobial Chemotherapy. 51(3). 599–603. 55 indexed citations
8.
9.
Ackermann, G. (2003). Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. Journal of Antimicrobial Chemotherapy. 51(3). 497–511. 94 indexed citations
10.
Ackermann, G, Yajarayma Tang-Feldman, Reiner Schaumann, et al.. (2003). Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clinical Microbiology and Infection. 9(6). 526–530. 39 indexed citations
11.
Tang-Feldman, Yajarayma, et al.. (2002). One-step cloning and expression of Clostridium difficile toxin B gene (tcdB). Molecular and Cellular Probes. 16(3). 179–183. 8 indexed citations
12.
Ackermann, G, et al.. (2001). Electroporation of DNA sequences from the pathogenicity locus (PaLoc) of toxigenic Clostridium difficile into a non-toxigenic strain. Molecular and Cellular Probes. 15(5). 301–306. 9 indexed citations
13.
Schaumann, Reiner, Wolfram Pönisch, Jörg Helbig, et al.. (2001). Pericarditis after Allogeneic Peripheral Blood Stem Cell Transplantation Caused by Legionella pneumophila (Non-serogroup 1). Infection. 29(1). 51–53. 6 indexed citations
14.
Ackermann, G, et al.. (2001). Rapidly Growing Tumor-Like Brain Lesion. Infection. 29(5). 278–279. 5 indexed citations
15.
Schaumann, Reiner, Kathy Stein, C. Eckhardt, G Ackermann, & Arne C. Rodloff. (2001). Infections Caused by Stenotrophomonas maltophilia - A Prospective Study. Infection. 29(4). 205–208. 31 indexed citations
16.
Schaumann, Reiner, et al.. (2000). In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria. International Journal of Antimicrobial Agents. 16(3). 225–232. 20 indexed citations
17.
Ackermann, G. (2000). In vitro activity of telithromycin (HMR 3647) and seven other antimicrobial agents against anaerobic bacteria. Journal of Antimicrobial Chemotherapy. 46(1). 115–119. 9 indexed citations
18.
Ackermann, G, et al.. (2000). Comparative Activity of Moxifloxacin in Vitro Against Obligately Anaerobic Bacteria. European Journal of Clinical Microbiology & Infectious Diseases. 19(3). 228–232. 55 indexed citations
19.
Ackermann, G, et al.. (2000). Chronic Factitious Illness Presenting as Munchausen's Gonarthritis. European Journal of Clinical Microbiology & Infectious Diseases. 19(1). 70–71. 1 indexed citations
20.
Schaumann, Reiner, et al.. (1999). In Vitro Activities of Gatifloxacin, Two Other Quinolones, and Five Nonquinolone Antimicrobials against Obligately Anaerobic Bacteria. Antimicrobial Agents and Chemotherapy. 43(11). 2783–2786. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mercedes Marı́n Breakdown of academic impact, for papers by Jin‐Yong Jeong Breakdown of academic impact, for papers by Steven P Gelone Breakdown of academic impact, for papers by Jennifer S. McDanel Breakdown of academic impact, for papers by M. Marín Breakdown of academic impact, for papers by Jin-Won Chung Breakdown of academic impact, for papers by Orna Nitzan Breakdown of academic impact, for papers by Hiroshige Mikamo Breakdown of academic impact, for papers by Nicole J. Pultz Breakdown of academic impact, for papers by Ali Hassoun
Rankless by CCL
2026